Antibody and use thereof
US12297265B2 · kind B2 · utility
0Cited by
1References
43Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 19, 2019 |
| Grant date | May 13, 2025 |
| Priority date | — |
| Expiry date | Sep 17, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding the antibody and fragment, and method for preparing the antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Also provided herein is a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs for the prevention and/or treatment of tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.